We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

5 hedge funds and large institutions have $2.58M invested in Blueprint Medicines in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 344 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

99% less funds holding

Funds holding: 354 → 5 (-349)

99.54% less ownership

Funds ownership: 99.58% → 0.04% (-100%)

100% less capital invested

Capital invested by funds: $8.24B → $2.58M (-$8.24B)

100% less funds holding in top 10

Funds holding in top 10: 29 → 0 (-29)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 344

Holders
5
Holders Change
-349
Holders Change %
-98.59%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-29
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
344
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
IA
IFP Advisors
Florida
+$2.06K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$822M
2
BlackRock
BlackRock
New York
-$784M
3
PCM
Pentwater Capital Management
Florida
-$500M
4
State Street
State Street
Massachusetts
-$286M
5
UBS Group
UBS Group
Switzerland
-$278M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$2.55M – – –
VanEck Associates
2
VanEck Associates
New York
$17K -$112K -872 -87%
IA
3
IFP Advisors
Florida
$8.54K +$2.06K +16 +32%
Osaic Holdings
4
Osaic Holdings
Arizona
$2.95K -$32.9K -255 -92%
HNB
5
Huntington National Bank
Ohio
$129 -$27.1K -210 -100%
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$822M -6,416,603 Closed
BlackRock
7
BlackRock
New York
– -$784M -6,118,428 Closed
PCM
8
Pentwater Capital Management
Florida
– -$500M -3,900,000 Closed
State Street
9
State Street
Massachusetts
– -$286M -2,230,980 Closed
UBS Group
10
UBS Group
Switzerland
– -$278M -2,167,028 Closed
Fidelity International
11
Fidelity International
Bermuda
– -$226M -1,759,500 Closed
UOC
12
UBS O'Connor
Illinois
– -$220M -1,713,587 Closed
Barclays
13
Barclays
United Kingdom
– -$200M -1,556,918 Closed
Geode Capital Management
14
Geode Capital Management
Massachusetts
– -$198M -1,541,013 Closed
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
– -$188M -1,464,968 Closed
GCL
16
Glazer Capital LLC
New York
– -$171M -1,331,300 Closed
Norges Bank
17
Norges Bank
Norway
– -$138M -1,074,936 Closed
BCM
18
Beryl Capital Management
California
– -$137M -1,067,224 Closed
AAM
19
Alpine Associates Management
Florida
– -$136M -1,060,307 Closed
DKCM
20
Davidson Kempner Capital Management
New York
– -$133M -1,035,100 Closed
Morgan Stanley
21
Morgan Stanley
New York
– -$132M -1,031,170 Closed
Macquarie Group
22
Macquarie Group
Australia
– -$118M -922,167 Closed
Goldman Sachs
23
Goldman Sachs
New York
– -$114M -891,287 Closed
SCS
24
Syquant Capital SAS
France
– -$103M -805,603 Closed
AllianceBernstein
25
AllianceBernstein
Tennessee
– -$98.1M -765,387 Closed
1
2 3 4 5

BPMC Hedge Fund Activity: Q3 2025 in Review

5 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2025, worth a combined $2.58M — down 100% from $8.24B a quarter earlier.

Sellers outnumbered buyers: 344 funds closed out of BPMC and 0 opened new positions — a net loss of 344 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $2.06K. The largest seller was Vanguard Group, exiting entirely with an estimated $822M sold.

  • 5 institutional investors held Blueprint Medicines (BPMC) as of Q3 2025, down from 354 in Q2 2025.
  • Funds reported $2.58M of Blueprint Medicines stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Blueprint Medicines positions in Q3 2025 and 344 closed out, a net change of -344 holders.
  • The largest Blueprint Medicines buyer in Q3 2025 was IFP Advisors, an estimated $2.06K added.
  • The largest Blueprint Medicines seller in Q3 2025 was Vanguard Group, an estimated $822M sold.

Based on aggregated 13F filings for Q3 2025.